PremiumMansukh Mandaviya,Minister of State today assured that the Government is monitoring supply of each COVID-19 essential drug. All drugs used in the management of COVID-19 are now available in India by ramping up production and increasing the imports. The availability of these drugs is being monitored by implementing three-pronged strategy of Supply Chain Management, Demand Side Management and Affordability.
Protocol Drugs:
Premium Premium Remdesivir
Enoxaparin
MethylPrednisolone
Dexamethasone
Tocilizumab
Ivermectin
Non-protocol Drugs:
Favipiravir
Amphotericin
Apixaban
CDSCO and NPPA are coordinating with manufacturers to enhance production and getting data about current stock, current capacities, Projected production for the May, 2021.
Remdesivir:
Number of plants producing Remdesivir increased from 20 to 60 resulting in 3 times more availability in just 25 days.
Production ramped up 10 times, from 10 lakhs vials/month in April’21 to ~1 crore/ month in May’21.
Toscilizumab injection:
It is made available in the country by importing 20 times more than what was being done in normal times.
Dexamethasone 0.5 mg tablets:
Production enhanced from 6-8 times within a month
Dexamethasone Injection production ramped up almost 2 times.
Enoxaparin Injection production increased 4 times in mere one month.
Methyl Prednisolone Injection:
Production increased almost 3 times in a months time.
Ivermectin 12 mg tab production enhanced in the country by ~5 times within a month from 150 lakhs in April to 770 lakhs in May,2021.
Favirpiravir:
A non-protocol drug but it is used to lower the virus load .
The production increased 4 times within a month
From 326.5 lakh in April,21 to 1644 lakh in May,21.
Amphoterecin B Injection:
Production ramped up ~ 3 times in a month.
3.80 lakh vials are in production and
3 lakh vials are being imported
Total 6.80 lakh vials will be available in the country.
Never miss a story! Stay connected and informed with Mint. Download our App Now!!
